Wenxuan Ni
Overview
Explore the profile of Wenxuan Ni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
33
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang F, Ge Y, Zhang Y, Cui Z, Lin S, Ni W, et al.
ACS Appl Mater Interfaces
. 2025 Jan;
17(2):2952-2965.
PMID: 39760335
Antibiotic resistance has become a critical health crisis globally. Traditional strategies using antibiotics can lead to drug-resistance, while inorganic antimicrobial agents can cause severe systemic toxicity. Here, we have developed...
2.
Wu Z, Yu W, Luo J, Shen G, Cui Z, Ni W, et al.
Eur J Med Res
. 2024 Jun;
29(1):323.
PMID: 38867262
Background: Abdominal aortic aneurysm (AAA) is a highly lethal cardiovascular disease. The aim of this research is to identify new biomarkers and therapeutic targets for the treatment of such deadly...
3.
Cui Z, He J, Zhu J, Ni W, Liu L, Bian Z, et al.
Clin Transl Med
. 2023 Apr;
13(4):e1239.
PMID: 37070251
Background: Accumulating studies have shown that La-related protein 1 (LARP1) is involved in the occurrence and development of various tumours. However, the expression pattern and biological role of LARP1 in...
4.
Tang X, Liang Y, Zhu Y, Xie C, Yao A, Chen L, et al.
Int J Nanomedicine
. 2015 Oct;
10:6227-41.
PMID: 26491294
Fatal fungal infections in central nervous system (CNS) can occur through hematogenous spread or direct extension. At present, hydrophobic amphotericin B (AMB) is the most effective antifungal drug in clinical...
5.
Tang X, Li Q, Zhu Y, Zheng D, Dai J, Ni W, et al.
Am J Transl Res
. 2015 Jun;
7(3):460-73.
PMID: 26045887
Tumors exploit immunoregulatory checkpoints to attenuate T cell responses as a means of circumventing immunologic rejection. By activating the inhibitory costimulatory pathway of Programmed Death 1 (PD1)/PDL1 which provides tumor...